Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Other Operating Expenses (2022 - 2024)

Adial Pharmaceuticals' Other Operating Expenses history spans 3 years, with the latest figure at -$1.5 million for Q1 2024.

  • For Q1 2024, Other Operating Expenses fell 326.48% year-over-year to -$1.5 million; the TTM value through Dec 2024 reached -$1.5 million, down 6.94%, while the annual FY2023 figure was -$471326.0, 104.07% down from the prior year.
  • Other Operating Expenses for Q1 2024 was -$1.5 million at Adial Pharmaceuticals, down from -$905087.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $289233.0 in Q2 2023 and bottomed at -$1.5 million in Q1 2024.
  • The 3-year median for Other Operating Expenses is -$341134.0 (2023), against an average of -$419768.3.
  • The largest annual shift saw Other Operating Expenses tumbled 2320.67% in 2023 before it plummeted 326.48% in 2024.
  • A 3-year view of Other Operating Expenses shows it stood at -$37390.0 in 2022, then crashed by 2320.67% to -$905087.0 in 2023, then plummeted by 60.75% to -$1.5 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Other Operating Expenses are -$1.5 million (Q1 2024), -$905087.0 (Q4 2023), and -$403530.0 (Q3 2023).